An Antibiotic-Responsive Mouse Model of Fulminant Ulcerative Colitis (original) (raw)
Figure 7
Amelioration of Colitis in dnKO Mice Through Simultaneous Neutralization of IFNγ and TNFα
(A) HE-stained sections of the rectums of dnKO mice treated with neutralizing antibodies to inflammatory cytokines. Colons from dnKO mice injected IP with 1 mg of neutralizing antibodies against IFNγ, TNFα, IFNγ + TNFα, or an isotype control (anti-PIP) at 2 and 3 wk of age were harvested at 4 wk of age.
(B–F) Quantitative morphometric analysis of the histopathology from dnKO mice treated with anti-PIP (isotype control), anti-IFNγ, anti-TNFα, or a combination of anti-IFNγ and anti-TNFα is shown. Crypt loss/dropout was measured by examining (B) the number of crypts per field (a field, 870 μm) and (C) crypt width. Epithelial proliferation was measured by (D) crypt height taken from the base of the crypt to the basal side of the surface epithelial cells.
(E and F) The ratio of goblet cells/epithelial cells per crypt (E) and surface epithelial heights (F) were quantified to examine goblet cell loss and barrier changes.
Shown for all measurements are the averages ± SEM from n = 5 mice per group. The F test results are (B) F(3,17) = 7.627, p = 0.0019; (C) F(3,17) = 7.467, p = 0.0021; (D) F(3,17) = 4.326, p = 0.0194; (E) F(3,17) = 11.45, p = 0.0002; and (F) F(3,17) = 3.664, p = 0.0334. All statistically significant differences (using Bonferroni's multiple comparison test; p < 0.05) between any two groups were indicated with a bracket. The exact _p_-value is listed unless p < 0.001 (indicated by ***).